Table S1.
Precision and accuracy of the LC–MS/MS method to determine nemonoxacin in human plasma or urine (in pre-study validation, n=3 days, six replicates per day)
| Matrix | Concentration (µg/mL)
|
RSD (%)
|
RE (%) | ||
|---|---|---|---|---|---|
| Added | Found | Intra-day | Inter-day | ||
| Plasma | 0.005 | 0.00491 | 14.3 | 10.8 | −1.9 |
| 0.01 | 0.00964 | 4.3 | 6.7 | −3.6 | |
| 0.50 | 0.499 | 2.3 | 5.3 | −0.2 | |
| 4.00 | 4.09 | 2.7 | 3.8 | 2.1 | |
| Urine | 0.2 | 0.203 | 5.1 | 8.6 | 1.4 |
| 0.4 | 0.384 | 3.2 | 7.1 | −3.9 | |
| 10.0 | 9.71 | 2.6 | 3.5 | −2.9 | |
| 160 | 158 | 5.5 | 4.5 | −1.1 | |
Abbreviations: LC–MS/MS, liquid chromatography–tandem mass spectrometry; RSD, relative standard deviation; RE, relative error.